標(biāo)題: Titlebook: Medication-Related Osteonecrosis of the Jaws; Bisphosphonates, Den Sven Otto Book 2015 Springer-Verlag Berlin Heidelberg 2015 BRONJ.Bisphos [打印本頁] 作者: CRUST 時(shí)間: 2025-3-21 16:20
書目名稱Medication-Related Osteonecrosis of the Jaws影響因子(影響力)
書目名稱Medication-Related Osteonecrosis of the Jaws影響因子(影響力)學(xué)科排名
書目名稱Medication-Related Osteonecrosis of the Jaws網(wǎng)絡(luò)公開度
書目名稱Medication-Related Osteonecrosis of the Jaws網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Medication-Related Osteonecrosis of the Jaws被引頻次
書目名稱Medication-Related Osteonecrosis of the Jaws被引頻次學(xué)科排名
書目名稱Medication-Related Osteonecrosis of the Jaws年度引用
書目名稱Medication-Related Osteonecrosis of the Jaws年度引用學(xué)科排名
書目名稱Medication-Related Osteonecrosis of the Jaws讀者反饋
書目名稱Medication-Related Osteonecrosis of the Jaws讀者反饋學(xué)科排名
作者: 冥想后 時(shí)間: 2025-3-21 21:52 作者: 值得贊賞 時(shí)間: 2025-3-22 01:25
Dental Implants in the Context Antiresorptive Drugs and Medication-Related Osteonecrosis of the JawJ and can even help in rehabilitation after MRONJ. Furthermore, as antiresorptive medication and especially bisphosphonate medication is frequent, and need for implant is frequent, too, there is emerging question on indication of dental implants in these increasing patient groups.作者: 大漩渦 時(shí)間: 2025-3-22 06:29
Epidemiology of Medication-Related Osteonecrosis of the Jaw,J/MRONJ with intravenous BP administration reached as high as 10 %, with the highest prevalence observed among multiple myeloma patients and the lowest prevalence measured among breast cancer patients.作者: 壕溝 時(shí)間: 2025-3-22 12:11
Microbiology and Antibiotics in the Context of Medication-Related Osteonecrosis of the Jaw,over the oral microbial bacteria and the bacteria expected in odontogenic infections. Additional factors have been discussed supporting the idea that bisphosphonates themselves attract bacteria at the bone as certain phyla and species could be found more frequently in osteonecrotic bone when compared to other infections.作者: NOCT 時(shí)間: 2025-3-22 15:41
Animal Models of Medication-Related Osteonecrosis of the Jaw,L inhibitors. The establishment of these models will be essential in propelling the field forward to understand the underlying pathophysiology of ONJ and ultimately finding a way to prevent or cure this debilitating condition.作者: Optic-Disk 時(shí)間: 2025-3-22 21:01 作者: Aggrandize 時(shí)間: 2025-3-22 23:51
Book 2015es and receiving intravenous administrations of nitrogen-containing bisphosphonates or subcutaneous administrations of denosumab, a monoclonal antibody. Less frequently?it may also be observed in patients with osteoporosis who are being treated with these antiresorptive drugs?.This textbook provides作者: noxious 時(shí)間: 2025-3-23 03:28
History of Osteonecrosis of the Jaw,les concerning prevention and treatment were similar to those of our days. The Bern convention banned the use of yellow phosphorous. In the following decades, the disease gradually disappeared from common knowledge, until Robert Marx described the first modern bisphosphonate-related osteonecrosis of the jaw in 2003.作者: capsaicin 時(shí)間: 2025-3-23 07:55
Pharmacological Aspects of Antiresorptive Drugs: Bisphosphonates and Denosumab,ic bone disease as well as other bone disorders with great success. Generally, bisphosphonates and denosumab are well tolerated and have few side effects. However, both substance classes of osteotrop antiresorptives have one side effect in common, namely, osteonecrosis of the jaw.作者: Fibrin 時(shí)間: 2025-3-23 13:47
Risk Factors for Medication-Related Osteonecrosis of the Jaw,ems similar or slightly higher compared with intravenous intake of nitrogen-containing BPs. Dental extractions and oncological dosing could be related to an increased risk of DRONJ. There are also increasing reports of osteonecrosis of the jaw related with antiangiogenic chemotherapeutics.作者: 男學(xué)院 時(shí)間: 2025-3-23 14:07 作者: Addictive 時(shí)間: 2025-3-23 21:36 作者: heirloom 時(shí)間: 2025-3-24 01:23
Practical guidelines for students and practitioners.First st.Osteonecrosis of the jaws is a well-known side-effect of?antiresorptive therapy that predominantly occurs in patients suffering from malignant diseases and receiving intravenous administrations of nitrogen-containing bisphosphonates or sub作者: Bph773 時(shí)間: 2025-3-24 03:10
https://doi.org/10.1007/978-3-662-43733-9BRONJ; Bisphosphonates; Denosumab; Implants; Malignant Diseases; Oral Surgery作者: Cholecystokinin 時(shí)間: 2025-3-24 09:30 作者: 用不完 時(shí)間: 2025-3-24 14:07 作者: 向下五度才偏 時(shí)間: 2025-3-24 17:58 作者: 騎師 時(shí)間: 2025-3-24 20:58
New and Innovative Treatment Strategies for Medication-Related Osteonecrosis of the Jaw,sis of the jaw due to bisphosphonate intake. More recently, regenerative concepts using stem cells from different sources and growth factors have been introduced for the treatment of medication-related osteonecrosis of the jaws. These new and innovative concepts seem to be promising future options in the management of osteonecrosis of the jaws.作者: 沐浴 時(shí)間: 2025-3-24 23:52
Risk Reduction of Medication-Related Osteonecrosis of the Jaw,k of ONJ can be, at least in part, reduced through control of a number of factors associated with increased likelihood of ONJ development. Robust evidence however remains limited. The aim of this chapter is to provide a comprehensive summary of available evidence upon risk-reduction measures for patients at risk of ONJ.作者: Osteons 時(shí)間: 2025-3-25 06:28
Pharmacological Aspects of Antiresorptive Drugs: Bisphosphonates and Denosumab,isorders including osteoporosis, metastatic bone disease and hypercalcemia of malignancy. Bisphosphonates are administered either orally or intravenously, while denosumab is injected subcutaneously. While bisphosphonates are not metabolized and have a strong affinity to the bone and a very long half作者: Detoxification 時(shí)間: 2025-3-25 07:28
Bisphosphonate and Denosumab Therapy: Fields of Application, preferred antiresorptive drug for malignant and nonmalignant diseases characterized by various kinds of bone loss. In general, bisphosphonates may be considered as treatment option for preserving bone mineral density in any disease accompanied by increased bone resorption, regardless of the pathoge作者: 類人猿 時(shí)間: 2025-3-25 15:09 作者: fibroblast 時(shí)間: 2025-3-25 17:23 作者: Externalize 時(shí)間: 2025-3-25 21:52 作者: 恩惠 時(shí)間: 2025-3-26 03:41
Imaging Modalities and Characteristics in Medication-Related Osteonecrosis of the Jaw,eonecrosis of the jaws (MRONJ). Various radiographic signs may be seen on panoramic radiographs, cone-beam computed tomography (CBCT), or multislice CT (MSCT) like sclerosis, persisting alveolar sockets, and lack of bone filling in extractions sites, osteolysis, and sequestration. While panoramic ra作者: Chauvinistic 時(shí)間: 2025-3-26 08:20 作者: 行為 時(shí)間: 2025-3-26 09:21
Local and Microvascular Free Flaps in Patients with Medication-Related Osteonecrosis of the Jaw,orptive drug-induced osteonecrosis) is considered a therapy-resistant form of osteonecrosis. Despite this conservative and surgical treatment, regimens have been attempted and recommended in the years since it was first identified..The key points after surgical debridement of the exposed bone sites 作者: 侵害 時(shí)間: 2025-3-26 14:09
Adjuvant Treatment Options in the Management of Medication-Related Osteonecrosis of the Jaw,[.]. The first objective of MRONJ treatment is to alleviate pain, reduce infection and stabilise the progression of disease with the closure of bone exposure. Several authors reported in literature two opposite approaches: surgical and non-surgical treatment [.]. Non-invasive treatment options inclu作者: 分開如此和諧 時(shí)間: 2025-3-26 20:30
New and Innovative Treatment Strategies for Medication-Related Osteonecrosis of the Jaw,sis of the jaw due to bisphosphonate intake. More recently, regenerative concepts using stem cells from different sources and growth factors have been introduced for the treatment of medication-related osteonecrosis of the jaws. These new and innovative concepts seem to be promising future options i作者: SEVER 時(shí)間: 2025-3-27 00:06
Microbiology and Antibiotics in the Context of Medication-Related Osteonecrosis of the Jaw,plain why the bone affected by osteonecrosis of the jaw lacks sufficient healing. Therefore, antibiotics are essential in the treatment of medication-related osteonecrosis of the jaw (MRONJ). Although antibiotic treatment as a singular therapy was able to heal MRONJ only in limited number of cases, 作者: 巨頭 時(shí)間: 2025-3-27 02:06
Histopathology of Medication-Related Osteonecrosis of the Jaw,en used for this condition, bisphosphonate-related osteonecrosis of the jaw (BRONJ) and medication-related osteonecrosis of the jaw (MRONJ) are applied throughout this chapter. BRONJ/MRONJ clinically presents as exposed bone of the mandible or the maxilla with further symptoms such as pain, drainage作者: 健談的人 時(shí)間: 2025-3-27 08:28
Pathogenesis of Medication-Related Osteonecrosis of the Jaw,thophysiology of the disease which has currently been renamed to medication-related osteonecrosis of the jaw (MRONJ). Several possible pathomechanisms including over-suppression of jawbone turnover, specific pathogens, antiangiogenic effects, and soft tissue toxicity have been proposed to be the mai作者: perjury 時(shí)間: 2025-3-27 13:00 作者: 讓空氣進(jìn)入 時(shí)間: 2025-3-27 14:07
Animal Models of Medication-Related Osteonecrosis of the Jaw,pite this extensive body of literature, when the clinical description of osteonecrosis of the jaw emerged in 2003/2004, the relative paucity of data describing how bisphosphonates affect the maxillofacial skeletal became clear. Over the past 10 years, there have been several dozen publications showi作者: abracadabra 時(shí)間: 2025-3-27 21:49 作者: 閃光你我 時(shí)間: 2025-3-28 01:35
Dental Implants in the Context Antiresorptive Drugs and Medication-Related Osteonecrosis of the Jawive drugs, the occurrence of MRONJ as an entity of osteonecrosis of jaw, and dental implants are multidimensional: Implants can trigger the occurrence of MRONJ; bisphosphonates and denosumab can alter implant osseointegration and clinical success, but implants are maybe useful in prophylaxis of MRON作者: Resign 時(shí)間: 2025-3-28 02:44 作者: CODE 時(shí)間: 2025-3-28 06:23 作者: configuration 時(shí)間: 2025-3-28 12:44 作者: 名詞 時(shí)間: 2025-3-28 14:42
Paolo Vescovi DDS, MSc,Maddalena Manfredi DDS, PhD,Elisabetta Merigo DDSeyond the approaches of conflict resolution and renewing a pInternational peacebuilding has reached an impasse. Its lofty ambitions have resulted in at best middling success, punctuated by moments of outright failure. The discrediting of the term ‘liberal peacebuilding’ has seen it evolve to respond作者: 花爭吵 時(shí)間: 2025-3-28 21:27
Riham M. Fliefel MSc,Pit J. Voss MD, DDSsion of the sixtieth an- versary of the International Law Commission. The Ludwig Maximilians University of Munich and the Humboldt University of Berlin are happy that you have followed our invitation. We are particularly proud that a majority of the members of the Int- national Law Commission have a作者: 不在灌木叢中 時(shí)間: 2025-3-28 22:58
Sebastian Hoefert DDS, MDernational Law Commission. The Ludwig Maximilians University of Munich and the Humboldt University of Berlin are happy that you have followed our invitation. We are particularly proud that a majority of the members of the Int- national Law Commission have accepted our invitation. The presence of one作者: Microgram 時(shí)間: 2025-3-29 05:13 作者: 寬容 時(shí)間: 2025-3-29 09:18 作者: 認(rèn)為 時(shí)間: 2025-3-29 13:12
Noam Yarom DMD,Stefano Fedele DDS, PhDsion of the sixtieth an- versary of the International Law Commission. The Ludwig Maximilians University of Munich and the Humboldt University of Berlin are happy that you have followed our invitation. We are particularly proud that a majority of the members of the Int- national Law Commission have a作者: ROOF 時(shí)間: 2025-3-29 19:20 作者: 取消 時(shí)間: 2025-3-29 21:34
Sebastian Hoefert DMD, MD,Feraydoon Sharghi DMD,Eva Engel DMDsion of the sixtieth an- versary of the International Law Commission. The Ludwig Maximilians University of Munich and the Humboldt University of Berlin are happy that you have followed our invitation. We are particularly proud that a majority of the members of the Int- national Law Commission have a作者: 拋物線 時(shí)間: 2025-3-30 02:18
Yorck Alexander Zebuhr MD, DMDernational Law Commission. The Ludwig Maximilians University of Munich and the Humboldt University of Berlin are happy that you have followed our invitation. We are particularly proud that a majority of the members of the Int- national Law Commission have accepted our invitation. The presence of one作者: 厚顏 時(shí)間: 2025-3-30 05:26
Matthias Troeltzsch MD, DMD,Markus Troeltzsch MD, DMD,Christoph Pache MD, DMD,Timothy Woodlock MDsion of the sixtieth an- versary of the International Law Commission. The Ludwig Maximilians University of Munich and the Humboldt University of Berlin are happy that you have followed our invitation. We are particularly proud that a majority of the members of the Int- national Law Commission have a作者: ETCH 時(shí)間: 2025-3-30 09:46
Sebastian Hoefert MD, DDS,Claudia Sade Hoefert DDS,Martin Widmann MDernational Law Commission. The Ludwig Maximilians University of Munich and the Humboldt University of Berlin are happy that you have followed our invitation. We are particularly proud that a majority of the members of the Int- national Law Commission have accepted our invitation. The presence of one作者: 遣返回國 時(shí)間: 2025-3-30 12:21 作者: anniversary 時(shí)間: 2025-3-30 17:36
Thomas Mücke MD, DDS, PhD,David A. Mitchell MBBS, BDS FDS, FRCSTenants Association of Punjab), advocates for the ownership of agricultural land. This resistance movement has given rise to a culture of resistance that liberated the peasants’ social life from military landlordism.作者: HEAVY 時(shí)間: 2025-3-30 20:46 作者: 背信 時(shí)間: 2025-3-31 03:37
Sven Otto MD, DMD, FEBOMFS,Tae-Geon Kwon DDS, PhD,Alexandre Th. Assaf MD, DMD, FEBOMFS作者: Extort 時(shí)間: 2025-3-31 07:32 作者: affect 時(shí)間: 2025-3-31 12:49
Bisphosphonate and Denosumab Therapy: Fields of Application,fects are still incompletely understood..Among bisphosphonates, zoledronic acid is the most potent and most thoroughly studied substance. Of all bisphosphonates, zoledronate displays the most beneficial effects in reducing fracture risk, antitumor activity, and additional effects but also the highes作者: 安裝 時(shí)間: 2025-3-31 13:56
Imaging Modalities and Characteristics in Medication-Related Osteonecrosis of the Jaw,t those are often not very specific. In the future, nuclear medicine imaging like combined SPECT/CT or PET/CT may further improve the diagnosis of MRONJ by combining functional and anatomical information.作者: esoteric 時(shí)間: 2025-3-31 19:16
Local and Microvascular Free Flaps in Patients with Medication-Related Osteonecrosis of the Jaw, planning logical individualized treatment. Many of these patients, often those worst affected, are suffering from malignant diseases with limited prognosis. Therefore, the choice of defect closure technique should also consider the individual situation of each patient; was the drug used for prophyl作者: COLIC 時(shí)間: 2025-3-31 21:51
Adjuvant Treatment Options in the Management of Medication-Related Osteonecrosis of the Jaw,s able to bear the side effects of prolonged therapeutic antibiotic schedules. The risk of opportunistic infections is high as well as the possible side effects to the respiratory tract with a high mortality rate in old and immune-compromised patients. The adjuvant treatments, such as hyperbaric oxy作者: consolidate 時(shí)間: 2025-4-1 05:32
Pathogenesis of Medication-Related Osteonecrosis of the Jaw,f the disease. Recently, osteonecrotic lesions in the jaw have been described under the treatment with denosumab as well, an antibody against RANK ligand. A better understanding of this entity and the involvement of the RANK-RANKL-OPG system might offer new insights towards a comprehensive understan作者: Bouquet 時(shí)間: 2025-4-1 08:59
